Effect of Topical Paromomycin on Cell‐mediated Immunity During Cutaneous Leishmaniasis

Frankenburg, Shoshana; Gross, Anat; Jonas, Flory; Klaus, Sidney N.

doi:10.1111/j.1365-4362.1993.tb00975.x

Cited by 7 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 50% cure rate is not as satisfactory as that obtained with antimonials or pentamidine, but sufficient to propose the use of this drug as an alternative in more complicated treatment circumstances 74–76 . The isolated use of the topical formulation of paromomycin is unsatisfactory and should not be chosen as first‐line therapy 77–79 . Several abstracts from the last World Congress of Leishmaniasis have shown different outcomes, but the data were not considered here.…”

Section: Discussionmentioning

confidence: 98%

Treatment of New World cutaneous leishmaniasis – a systematic review with a meta‐analysis

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Treatment of New World cutaneous leishmaniasis – a systematic review with a meta‐analysis

et al. 2008

View full text Add to dashboard Cite

show abstract

“…It would also clearly be useful to know how the early treatment of CL affects the development of the beneficial Th1 response (Frankenburg et al, 1993b;Darabi et al, 2002;Machado et al, 2002). If chemotherapy given early in the disease process leads to parasite death, antigen release and subsequent immunization, it should be possible to prevent the development of clinical disease (i.e.…”

Section: Discussionmentioning

confidence: 99%

“…There is some worrying evidence indicating that chemotherapy may delay or even prevent the development of protective immunity (Frankenburg et al, 1993b;Darabi et al, 2002). This may explain why, in cases of CL caused by L. braziliensis, Machado et al (2002) were unable to prevent the ulceration of the developing lesions by the early administration of antimonials.…”

mentioning

confidence: 99%

The flow-cytometry-based evaluation of cellular immunity in cases of cutaneous leishmaniasis and healthy controls from the endemic area in southern Israel

Fishman¹,

Bazarsky²,

Sneir³

et al. 2006

Annals of Tropical Medicine & Parasitology

View full text Add to dashboard Cite

Only limited data are available on the early immunological events associated with human cutaneous leishmaniasis (CL). In this study, peripheral-blood mononuclear cells were obtained from 66 individuals (34 patients with cutaneous lesions and 32 apparently healthy controls) who had each spent no more than 3 months in the endemic region of Qetzioth, in southern Israel. These cells' responses to Leishmania major antigen were then explored, by the flow-cytometry-based evaluation of blast transformation (BT). The lymphocytes from 17 (50%) of the patients but only one (3%) of the controls displayed BT. When, in an ELISA, most (52) of the subjects were checked for anti-L. major antibodies, none of the 22 controls investigated but 19 (63%) of the 30 patients were found seropositive. Although 14 (47%) of the 30 patients who were checked for antibodies were BT-positive, the seropositive patients were not significantly more or less likely to be BT-positive than the seronegative patients (P<0.919). These data indicate that, in CL, the hosts' cellular and humoral responses develop independently within the first 3 months post-infection, but further investigation is required to confirm this hypothesis.

show abstract

“…Our group recently reported potent antileishmanial activity of one 8-aminosubstituted aminoquinoline that can be orally administered (24). There are some other compounds with interesting possibilities for further development as antileishmanial drugs (24)(25)(26)(27). Compounds isolated from S. lycocarpum have already demonstrated great potential as antimicrobials and cytotoxic products (10)(11)(12)(13)(14)(15)(16)(17)(18).…”

Section: Discussionmentioning

confidence: 99%

A New Antileishmanial Preparation of Combined Solamargine and Solasonine Heals Cutaneous Leishmaniasis through Different Immunochemical Pathways

Lezama-Dávila

McChesney

Bastos

et al. 2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Little has been done during the past 100 years to develop new antileishmanial drugs. Most infected individuals live in poor countries and have a low cash income to be attractive targets to pharmaceutical corporations. Two heterosidic steroids, solamargine and solasonine, initially identified as major components of the Brazilian plant Solanum lycocarpum, were tested for leishmanicidal activity. Both alkaloids killed intracellular and extracellular Leishmania mexicana parasites more efficiently than the reference drug sodium stibogluconate. A total of 10 M each individual alkaloid significantly reduced parasite counts in infected macrophages and dendritic cells. In vivo treatment of C57BL/6 mice with a standardized topical preparation containing solamargine (45.1%) and solasonine (44.4%) gave significant reductions in lesion sizes and parasite counts recovered from lesions. Alkaloids present different immunochemical pathways in macrophages and dendritic cells. We conclude that this topical preparation is effective and a potential new and inexpensive treatment for cutaneous leishmaniasis.

show abstract

Effect of Topical Paromomycin on Cell‐mediated Immunity During Cutaneous Leishmaniasis

Abstract: These results suggest that topical paromomycin treatment delays the development of cell-mediated immunity but does not affect the levels of immunity that are eventually achieved.

Cited by 7 publications

References 8 publications

Treatment of New World cutaneous leishmaniasis – a systematic review with a meta‐analysis

Treatment of New World cutaneous leishmaniasis – a systematic review with a meta‐analysis

The flow-cytometry-based evaluation of cellular immunity in cases of cutaneous leishmaniasis and healthy controls from the endemic area in southern Israel

A New Antileishmanial Preparation of Combined Solamargine and Solasonine Heals Cutaneous Leishmaniasis through Different Immunochemical Pathways

Contact Info

Product

Resources

About